Geriatric assessment for older adults with lung cancer getting chemotherapy and radiation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a special geriatric assessment can help manage side effects for adults aged 60 and older with non-small cell lung cancer who are starting a new treatment plan that includes chemotherapy and radiation. It aims to improve quality of life and treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years or older with non-small cell lung cancer that cannot be removed by surgery.
- You plan to start a new treatment including chemotherapy (or similar drugs) combined with radiation within 4 to 6 weeks.
- You may have cancer that has spread to only one small spot outside the lung area (like a single brain metastasis or a single adrenal spot).
- You must be able to understand English, Spanish, or Mandarin, or have a healthcare proxy who can consent for you.
- You cannot have surgery planned within the next 3 months.
- You cannot have more than one area where cancer has spread (like both brain and liver).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special geriatric assessment (a check-up for older adults) and extra support can help people aged 60+ with head and neck cancer feel better during chemotherapy and radiation. It also looks at how this helps their family or friend caregivers.
This study looks at how a geriatric assessment can help older adults with early-stage lung cancer who are getting a precise type of radiation therapy called SBRT. The goal is to understand their needs and improve care.
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
This trial tests approved cancer drugs in people aged 70 and older with non-small-cell lung cancer who haven't had systemic treatment before. The goal is to see how well these drugs work in this older population.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
Hear when a new Stage III Lung Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.